Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.
October 9, 2013
This is the first medical food product to incorporate vitamin K2, targeting bone health while protecting cardiovascular health. This represents an exclusive license for the bone health category in medical foods.
"Medical foods is a unique and exciting category providing therapeutic benefits under a physician's care," said Frode March Bohan, chairman of NattoPharma ASA. "The incorporation of MenaQ7 Crystals in Primus Pharmaceuticals' Fosteum PLUS demonstrates that NattoPharma has met recognized scientific principles and entered the prescription, therapeutic drug medical market with MenaQ7."
Fosteum PLUS is for the clinical dietary management of the metabolic processes associated with osteopenia and osteoporosis with MenaQ7 vitamin K2 for improved bone results and cardiac safety. Fosteum PLUS can be used with a physician's prescription and is available in the U.S.
"Fosteum PLUS represents a ground-breaking development for bone health, as the inclusion of ultra-high purity; patented MenaQ7 is based on the unique three-year study, published in Osteoporosis International," said Eric Anderson, global vice president of marketing, NattoPharma. "The study demonstrates MenaQ7's clear preservation of bone constitution and strength in menopausal women."
The company released its MenaQ7 vitamin K2 crystals in June 2013.
You May Also Like
Here's why creatine sales are surging this past yearFeb 21, 2024
DSHEA's 25th anniversary: Industry vets, critics respondFeb 21, 2024
The Month in 2: Sports – videoFeb 21, 2024
Tianeptine sales spur another FDA warning, action by state lawmakersFeb 20, 2024